231 related articles for article (PubMed ID: 24424703)
41. Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory.
Kuypers KP; de la Torre R; Farre M; Pujadas M; Ramaekers JG
Br J Pharmacol; 2013 Feb; 168(3):607-17. PubMed ID: 22946487
[TBL] [Abstract][Full Text] [Related]
42. Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK.
Singer LT; Moore DG; Min MO; Goodwin J; Turner JJ; Fulton S; Parrott AC
Hum Psychopharmacol; 2015 Jul; 30(4):290-4. PubMed ID: 26216565
[TBL] [Abstract][Full Text] [Related]
43. Plasma drug concentrations and physiological measures in 'dance party' participants.
Irvine RJ; Keane M; Felgate P; McCann UD; Callaghan PD; White JM
Neuropsychopharmacology; 2006 Feb; 31(2):424-30. PubMed ID: 16192986
[TBL] [Abstract][Full Text] [Related]
44. Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat.
Connor TJ; McNamara MG; Finn D; Currid A; O'Malley M; Redmond AM; Kelly JP; Leonard BE
Immunopharmacology; 1998 Jan; 38(3):253-60. PubMed ID: 9506825
[TBL] [Abstract][Full Text] [Related]
45. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.
Biezonski DK; Meyer JS
J Neurochem; 2010 Feb; 112(4):951-62. PubMed ID: 20002520
[TBL] [Abstract][Full Text] [Related]
46. Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change.
Parrott AC
Neuropsychobiology; 2000; 42(1):17-24. PubMed ID: 10867552
[TBL] [Abstract][Full Text] [Related]
47. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
McCann UD; Slate SO; Ricaurte GA
Drug Saf; 1996 Aug; 15(2):107-15. PubMed ID: 8884162
[TBL] [Abstract][Full Text] [Related]
48. One-year outcomes of prenatal exposure to MDMA and other recreational drugs.
Singer LT; Moore DG; Min MO; Goodwin J; Turner JJ; Fulton S; Parrott AC
Pediatrics; 2012 Sep; 130(3):407-13. PubMed ID: 22908109
[TBL] [Abstract][Full Text] [Related]
49. Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss.
Bosker WM; Kuypers KP; Conen S; Ramaekers JG
Psychopharmacology (Berl); 2010 Mar; 209(1):69-76. PubMed ID: 20084368
[TBL] [Abstract][Full Text] [Related]
50. MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014).
Parrott AC
Hum Psychopharmacol; 2014 Mar; 29(2):109-19. PubMed ID: 24590542
[TBL] [Abstract][Full Text] [Related]
51. RETRACTED: Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
Ricaurte GA; Yuan J; Hatzidimitriou G; Cord BJ; McCann UD
Science; 2002 Sep; 297(5590):2260-3. PubMed ID: 12351788
[TBL] [Abstract][Full Text] [Related]
52. A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction.
Darracq MA; Thornton SL; Minns AB; Gerona RR
J Psychoactive Drugs; 2016; 48(5):351-354. PubMed ID: 27636207
[TBL] [Abstract][Full Text] [Related]
53. Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users.
Allott K; Canny BK; Broadbear JH; Stepto NK; Murphy B; Redman J
J Psychopharmacol; 2009 Sep; 23(7):759-74. PubMed ID: 18562414
[TBL] [Abstract][Full Text] [Related]
54. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management.
Hall AP; Henry JA
Br J Anaesth; 2006 Jun; 96(6):678-85. PubMed ID: 16595612
[TBL] [Abstract][Full Text] [Related]
55. Perinatal hypothalamic-pituitary-adrenal axis regulation among women with eating disorders and their infants.
Easter A; Taborelli E; Bye A; Zunszain PA; Pariante CM; Treasure J; Schmidt U; Micali N
Psychoneuroendocrinology; 2017 Feb; 76():127-134. PubMed ID: 27914245
[TBL] [Abstract][Full Text] [Related]
56. A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation.
Mechan AO; O'Shea E; Elliott JM; Colado MI; Green AR
Psychopharmacology (Berl); 2001 Jun; 155(4):413-8. PubMed ID: 11441431
[TBL] [Abstract][Full Text] [Related]
57. Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users.
Daumann J; Schnitker R; Weidemann J; Schnell K; Thron A; Gouzoulis-Mayfrank E
Neuroreport; 2003 Oct; 14(15):1983-7. PubMed ID: 14561934
[TBL] [Abstract][Full Text] [Related]
58. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
[TBL] [Abstract][Full Text] [Related]
59. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
Gouzoulis-Mayfrank E; Daumann J
Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
[TBL] [Abstract][Full Text] [Related]
60. Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat.
Koprich JB; Campbell NG; Lipton JW
Brain Res Dev Brain Res; 2003 Dec; 147(1-2):177-82. PubMed ID: 14741762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
